The NeurologyLive® Parkinson disease Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with the movement disorder.
Cognitive Impairments in Activities of Daily Living Predict Conversion to Parkinson Disease Dementia
January 26th 2023After a follow-up of nearly 4 years, nearly half of the patients (n = 10) with baseline classification of cognitive IADL impairment and mild cognitive impairment converted to dementia.
Mesdopetam Fails to Improve ON Time But Shows Anti-Dyskinesia Effects in Parkinson Disease
January 25th 2023Mesdopetam showed significant effects on the secondary end point of Unified Dyskinesia Rating Scale, an assessment of involuntary movements associated with long-term treatment with dopaminergic medication.
Research Identifies Protective Drugs Toward Parkinson Disease, Warranting Future Consideration
January 16th 2023Plain sulfonamide diuretics was identified as a drug chemical subgroup potentially inversely associated with Parkinson disease risk, while weaker signals included insulin and ß2-adrenergic agonists.
Pimavanserin Lowers Mortality Better in Parkinson Disease Than Other Atypical Antipsychotics
January 6th 2023Findings from a large-scale trial of adults aged 65 and older with Parkinson disease showed that treatment with pimavanserin was associated with lower risk of mortality than other atypical antipsychotics.
Range of Risk Factors, Comorbidities, and Prodromal Features Identified Prior to Parkinson Disease
December 9th 2022Subsequent diagnosis of Parkinson disease was associated with a range of risk factors such as alcohol misuse and traumatic head injury, along with several other comorbidities and prodromal features.